Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P2V-101
- Development stage
- Unknown
- Lead developer
- P2V Bioscience
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
P2V-101 is a recombinant protein vaccine candidate developed by P2V Bioscience for the prevention of COVID-19. The vaccine is based on a virus-like particle (VLP) platform designed to present the SARS-CoV-2 spike protein in a highly immunogenic format. Specifically, it may incorporate the '2P' (proline-2-variant) stabilization mutations, which involve the substitution of two consecutive residues in the S2 subunit with prolines to maintain the spike protein in its prefusion conformation. This structural stabilization is intended to enhance the elicitation of neutralizing antibodies. P2V Bioscience, a biotechnology company based in France, initiated clinical development to evaluate the safety and immunogenicity of P2V-101 in healthy adults.
- Other names
- P2V vaccineP-2V vaccineP 2V vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on P2V-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P2V-101.